Schumacher, J. Shapiro, G. Silver, W. Smith, J. Snyder, J. Sullivan, B. Troupin,L. Tuttle, C. Vance, M. Weerasinghe, R.Weinstein, D. Weiss, R. Weiss, P. Weiss-man, F. Whitehouse, K. Williams, N.Winer, M. Wofford, C. Wysham, A.Zayed, L. Zemel. References 1. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secre- tory dysfunction and insulin resistance inthe pathogenesis of type 2 diabetes melli-tus.J Clin Invest 104:787–794, 1999 2. Haffner SM, Mykkanen L, Festa A, Burkes JP, Stern MP: Insulin-resistant prediabeticsubjects have more atherogenic risk fac-tors than insulin-sensitive prediabeticsubjects: implications for preventing cor-onary heart disease during the prediabeticstate. Circulation 101:975–980, 2000 3. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16. Over-view of 6 year’s therapy of type II diabetes:a progressive disease. Diabetes 44:1249– 1258, 1995 4. UK Prospective Diabetes Study Group: